In melanoma, the level of tumor-related lymphangiogenesis correlates with the rate of SLN metastases [8]. Moreover, recent studies demonstrated that tumor cells in several malignancies can induce lymphangiogenesis in SLNs before metastasis [6, 9–12]. Although it is known that structural changes to SLNs are required for premetastatic conditions, changes to regional LNs remain unexplored. Lymphangiogenic factors promoting formation of tumor lymphatics and metastasis of tumor cells to LNs have been identified [13,

14]. These factors include the secreted glycoproteins vascular endothelial growth factor (VEGF)-C and VEGF-D, which activate VEGF receptor-3 (VEGFR-3), a cell surface receptor Selleckchem RGFP966 tyrosine kinase expressed on lymphatic endothelium [15, 16]. VEGF-C or VEGF-D overexpression

is known to promote tumor lymphangiogenesis and tumor dissemination in animal models [17–19], whereas inhibition of VEGFR-3 signaling blocks these phenomena [20]. Similarly, in human cancers, increased VEGF-C or VEGF-D expression is related to metastasis and poor prognosis [13, 14], whereas VEGF-A and VEGF-C-induced lymphangiogenesis in LNs contributes to metastasis [10, 12]. These observations support that VEGF-C or VEGF-D and VEGFR-3 signaling pathway is required for tumor lymphangiogenesis induction. However, much check details remains undiscovered about contribution of this pathway to lymphangiogenesis in the regional LNs proximal to tumors. Appropriate Cisplatin price animal models are necessary to study detailed changes to regional LNs during lymphatic metastasis. To characterize LN metastasis, we established a mouse model of spontaneous LN

metastasis according to Iwahashi et al. in which injection of B16 melanoma cells into mouse PXD101 order tongues is known to replicate spontaneous cervical LN metastasis [21]. Although regional LNs must be affected by primary tumors and metastatic SLNs, conclusive evidence for this phenomenon does not exist. We focused on tumor-related lymphangiogenesis in LNs proximate to oral melanoma in mice. Our study had three goals: 1. To histologically characterize regional LNs proximal to tumors.   2. To investigate increased lymphangiogenesis in LNs by histomorphometric analysis of lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) -positive areas.   3. To examine an interaction of VEGF-C with VEGFR-3 in LN lymphangiogenesis using dual immunofluorescence.   Our results indicate that tumor-associated LNs show extensive lymphangiogenesis, which may facilitate further metastasis. Methods Cell culture The mouse melanoma cell line, B16/F10 (RCB2630), was provided by the RIKEN BRC through the National BioResource Center through the National Bio-Resource Project of the Ministry of Education, Culture, Sports and Technology (Ibaraki, Japan). Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum and penicillin/streptomycin.